Retrospective analysis shows CAR T-cell therapy improves response rate in relapsed/refractory T cell/histiocyte-rich large B-cell lymphoma, suggesting manageable toxicity.
Key Points
This research aims to evaluate the efficacy and safety of CD19-directed CAR T-cell therapy in patients with R/R T cell/histiocyte-rich large B-cell lymphoma.
Retrospective analysis of adult patients with R/R THRLBCL from 6 Australian centers.
Patients received CD19-directed CAR T-cell therapy; either Axicabtagene ciloleucel or Tisagenlecleucel.
Response assessment was conducted using Lugano criteria and survival outcomes calculated via Kaplan-Meier methodology.
67% overall response rate at day 30, with 56% complete responses.
44% one-year progression-free survival, with variations between therapies.
60% incidence of cytokine release syndrome and 40% for neurotoxicity, with manageable grades.